The DOI matches its Crossref record; 15 of the 16 references it cites were found in a registry or an index.
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Open accessAbstract
BACKGROUND: Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in phase 2 studies. We conducted a phase 3 trial to evaluate the safety and efficacy of 52 weeks of treatment with evolocumab. METHODS: We stratified patients with hyperlipidemia according to the risk categories outlined by the Adult Treatment Panel III of the National Cholesterol Education Program. On the basis of this classification, patients were started on background lipid-lowering therapy with diet alone or diet plus atorvastatin at a dose of 10 mg daily, atorvastatin at a dose of 80 mg daily, or atorvastatin at a dose of 80 mg daily plus ezetimibe at a dose of 10 mg daily, for a run-in period of 4 to 12 weeks. Patients with an LDL cholesterol level of 75 mg per deciliter (1.9 mmol per liter) or higher were then randomly assigned in a 2:1 ratio to receive either evolocumab (420 mg) or placebo every 4 weeks. The primary end point was the percent change from baseline in LDL cholesterol, as measured by means of ultracentrifugation, at week 52. RESULTS: Among the 901 patients included in the primary analysis, the overall least-squares mean (±SE) reduction in LDL cholesterol from baseline in the evolocumab group, taking into account the change in the placebo group, was 57.0±2.1% (P<0.001). The mean reduction was 55.7±4.2% among patients who underwent background therapy with diet alone, 61.6±2.6% among those who received 10 mg of atorvastatin, 56.8±5.3% among those who received 80 mg of atorvastatin, and 48.5±5.2% among those who received a combination of 80 mg of atorvastatin and 10 mg of ezetimibe (P<0.001 for all comparisons). Evolocumab treatment also significantly reduced levels of apolipoprotein B, non-high-density lipoprotein cholesterol, lipoprotein(a), and triglycerides. The most common adverse events were nasopharyngitis, upper respiratory tract infection, influenza, and back pain. CONCLUSIONS: At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels in patients with a range of cardiovascular risks. (Funded by Amgen; DESCARTES ClinicalTrials.gov number, NCT01516879.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatment of hyperlipidemic patients with monoclonal antibodies that target and inactivate PCSK9 results in increased hepatic LDLR expression and significantly reduced plasma LDL-C40,41.”
From RNF130 Regulates LDLR Availability and Plasma LDL Cholesterol Levels (2023) · cites this paper as [41]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment with PCSK9 inhibitors reduces LDL-C by approximately − 60% [75–79].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [79]
The cited source says what the claim attributes to it.
In the citing paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“ASO silencing of Rnf130 resulted in a 50% decrease in LDL-C, a change comparable to inhibiting PCSK940,41, further supporting that RNF130 is a significant regulator of LDLR and LDL-C levels.”
From RNF130 Regulates LDLR Availability and Plasma LDL Cholesterol Levels (2023) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Stein, E. A., Gipe, D., Bergeron, J., Gaudet, D., Weiss, R., Dufour, R., Wu, R., & Pordy, R. C. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60771-5 · Cited by 579
Self-citationMcKenney, J. M., Koren, M. J., Kereiakes, D. J., Hanotin, C., Ferrand, A.-C., & Stein, E. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.007 · Cited by 514
Self-citationRaal, F. J., Scott, R. C., Somaratne, R. M., Bridges, I. M., Li, G., Wasserman, S. M., & Stein, E. A. (2012) · Circulation · doi:10.1161/circulationaha.112.144055 · Cited by 506
Self-citationAtorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
Roth, E. M., McKenney, J. M., Hanotin, C., Asset, G., & Stein, E. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201832 · Cited by 462
Self-citationLambert (2012) · doi:10.1194/jlr.r026658 · Cited by 448
Sullivan, D., Olsson, A. G., Scott, R., Kim, J. B., Xue, A., Gebski, V., Wasserman, S. M., & Stein, E. A. (2012) · JAMA · doi:10.1001/jama.2012.25790 · Cited by 447
Self-citationGiugliano, R. P., Desai, N. R., Kohli, P., Rogers, W. J., Somaratne, R. M., Huang, F., Liu, T., Mohanavelu, S., Hoffman, E. B., McDonald, S. T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61770-x · Cited by 428
Self-citation
Flagged first, then by citations
1 of the 16 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 501–600 of 722
The Impact of PCSK9 Gene Polymorphisms on Ischemic Stroke: A Systematic Review and Meta-Analysis
Wang, J., Li, S., Ren, Y., Wang, G., & Li, W. (2024) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2303062 · Cited by 5
The Essence of Lipoproteins in Cardiovascular Health and Diseases Treated by Photodynamic Therapy
Wańczura, P. M., Aebisher, D., Iwański, M. A., Myśliwiec, A., Dynarowicz, K., & Bartusik‐Aebisher, D. (2024) · Biomedicines · doi:10.3390/biomedicines12050961 · Cited by 5
Wu, Z.-M., Kan, J., Ye, F., You, W., Wu, X., Tian, N., Lin, S., Ge, Z., Liu, Z., Li, X.-B., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.06.004 · Cited by 5
PCSK9 Inhibitors: The Next Frontier in Low-Density Lipoprotein Lowering
Jialal, I., & Patel, S. B. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.1503 · Cited by 5
Significance of Monoclonal PCSK9-Antibodies - New Approaches to the Therapy of Hypercholesterolemia
Neumann, C. L., Schettler, E., & Schettler, V. J. J. (2016) · Blood Purification · doi:10.1159/000443140 · Cited by 6
Denegri, A., Petrova-Slater, I., Pasotti, E., Rossi, M. G., Pedrazzini, G., Moccetti, T., & Moccetti, M. (2016) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000360 · Cited by 5
Volta, A., Hovingh, G. K., & Grefhorst, A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000489 · Cited by 5
(2016) · Australian Prescriber · doi:10.18773/austprescr.2016.078 · Cited by 5
Apolipoprotein E Mimetic Peptides: Cholesterol-Dependent and Cholesterol-Independent Properties
Garber, D. W., Goldberg, D., & Anantharamaiah, G. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-17350-4_10 · Cited by 5
Effects of monoclonal antibodies against PCSK9 on clinical cardiovascular events
Zhu, Y., Shen, X., Jiang, Q., Wang, Z., Wang, Z., Dong, X., Li, J., Han, Q., Zhao, J., Wang, B., et al. (2017) · Herz · doi:10.1007/s00059-017-4640-8 · Cited by 5
Vettor, R., & Serra, R. (2018) · Italian Journal of Medicine · doi:10.4081/itjm.2018.1062 · Cited by 5
THE EFFECT OF EVOLOCUMAB ALONE AND IN COMBINATION WITH ATORVASTATIN ON LIPID PROFILE
Saud, A., Ali, N. A. J., Gali, F. Y., & Hadi, N. R. (2021) · Wiadomości Lekarskie · doi:10.36740/wlek202112111 · Cited by 4
Akiyama, Y., Katsuki, S., Koga, Y., Yamamoto, M., Hironaga, K., Suematsu, N., Miyata, K., Mukai, Y., Inoue, S., Nishi, J.-I., et al. (2025) · Journal of Cardiology · doi:10.1016/j.jjcc.2025.04.002 · Cited by 4
Hu, X., Liu, Y., Yuan, W., Zhang, Z., Li, S., Cheng, A., Yu, Q., Guo, H., Zou, Y., Li, M. L., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.041251 · Cited by 4
Innovative molecular intervention and precision therapy for atherosclerosis
Wang, Z., Peng, W., Huang, L., Zhang, Y., Yang, J., Chen, X., Liu, X., Li, F., & Zhang, Q. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1652933 · Cited by 4
Incorporation of PCSK9 inhibitors into prevention of atherosclerotic cardiovascular disease
Wójcik, C. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1376570 · Cited by 4
To test, or not to test: that is the question for the future of lipoprotein(a)
Ellis, K. L., Chakraborty, A., Moses, E. K., & Watts, G. F. (2019) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2019.1596799 · Cited by 4
A Novel Monoclonal Antibody 1D2 That Broadly Inhibits Clinically Important Aspergillus Species
Lian, X., Scott-Thomas, A., Lewis, J. G., Bhatia, M., & Chambers, S. T. (2022) · Journal of Fungi · doi:10.3390/jof8090960 · Cited by 4
Small Interfering Ribonucleic Acid as Lipid-Lowering Therapy: Inclisiran in Focus
Rakočević, J., Dobric, M. R., Vučić, R. M., Furtula, M., Zaletel, I. V., Milutinović, K., Ilijevski, A., Labudović‐Borović, M., Tomasevic, M. V., & Bajčetić, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24066012 · Cited by 5
Towards Optimal Cardiovascular Health: A Comprehensive Review of Preventive Strategies
Branigan, P., Duong, Y. V., Abdulfattah, A., Sabu, J., Mallappallil, M. C., & John, S. (2024) · Cureus · doi:10.7759/cureus.60877 · Cited by 4
Targeting PCSK9 beyond the liver: evidence from experimental and clinical studies
Dalt, L. D., Baragetti, A., & Norata, G. D. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2482545 · Cited by 4
Sheng, F., Miyawaki, K., Osada, N., Tanaka, S., Liu, Z., & Shinke, T. (2025) · Circulation Reports · doi:10.1253/circrep.cr-25-0109 · Cited by 4
Report of the American College of Cardiology (ACC) Scientific Sessions 2014, Washington, DC
Kusunose, K. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0411 · Cited by 4
Controllo lipidico in pazienti ad elevato rischio cardiovascolare: focus sull’inibizione di PCSK9
Filardi, P. P., Paolillo, S., & Trimarco, B. (2015) · Giornale italiano di cardiologia · doi:10.1714/1776.19250 · Cited by 4
Mühlbacher, A. C., Kaczynski, A., Dippel, F. W., & Bethge, S. (2018) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462318000247 · Cited by 4
Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors
Nicholls, S. J. (2018) · European Cardiology Review · doi:10.15420/ecr.2018.3.2 · Cited by 4
Peng, Y., Chen, G., & Zheng, H. (2020) · PubMed Central · doi:10.12122/j.issn.1673-4254.2020.08.11 · Cited by 4
Majithia, A. R., Altshuler, D., & Hirschhorn, J. N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00004-6 · Cited by 4
Dyslipidemia in Women: Etiology and Management
Rajai, N., & Welty, F. K. (2021) · Stroke revisited · doi:10.1007/978-981-16-3923-4_16 · Cited by 6
An update on emerging drugs for the treatment of hypercholesterolemia
Nelson, A. J., Bubb, K. J., & Nicholls, S. J. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.2009801 · Cited by 4
PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
Yang, E. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.263 · Cited by 4
PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges
Rashid, H. N. Z., Meredith, I. T., & Nasis, A. (2017) · Heart Lung and Circulation · doi:10.1016/j.hlc.2016.12.005 · Cited by 4
Wang, E. Q., Plotka, A., Salageanu, J., Baltrukonis, D. J., Mridha, K., Frederich, R. C., & Sullivan, B. E. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.454 · Cited by 4
Jaiswal, V., Goyal, A., Deb, N., Shama, N., Mittal, V., Rajak, K., Halder, A., Khadka, S., Kumar, T., Ahmed, R., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101311 · Cited by 3
Gupta, J., & Gupta, R. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467216666221202144813 · Cited by 3
Nasso, G., Vignaroli, W., Amodeo, V., Bartolomucci, F., Larosa, C., Contegiacomo, G., Demola, M. A., Girasoli, C., Valenzano, A., Fiore, F., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13102987 · Cited by 4
He, W. B., Jape, D., Nanayakkara, S., & Shaw, J. A. (2024) · Heart Lung and Circulation · doi:10.1016/j.hlc.2024.07.012 · Cited by 3
Ma, H., Ma, W., Liu, Y., Chen, L., & Ding, P. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm26980 · Cited by 3
Statins and PCSK9 Inhibitors: Defining the Correct Patients
Farnier, M. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_9 · Cited by 3
12. Some chronobiological investigations relevant to cholesterol
Cornélissen, G., Singh, R. K., Singh, R. K., Singh, R. B., & Meester, F. D. (2016) · Wageningen Academic Publishers eBooks · doi:10.3920/978-90-8686-821-6_12 · Cited by 3
Safety and efficacy of alirocumab
Shukla, A. K., & Mehani, R. (2019) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_406_19 · Cited by 3
Two new lipid-regulating drugs
BMJ Publishing Group Ltd (2016) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2016.2.0381 · Cited by 3
Bonilha, I., Gomes, É. I. L., do Carmo, H. R. P., Breder, I. S. S., Barreto, J., Breder, J. D. S. C., Munhoz, D., de Carvalho, L. S. F., Quinaglia, T., Kimura-Medorima, S. T., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074108 · Cited by 3
Li, W., Sun, L., & Yan, S. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1375040 · Cited by 4
Li, J., Huang, S., Hu, X. X., & Chen, J. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s493912 · Cited by 3
New Biotechnological Treatments for Lipid Disorders
Valencia‐Enciso, N., & Mendivil, C. O. (2018) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.18002577 · Cited by 3
Statin Intolerance: an Overview of the Current Status and Possible Treatment Options
Suh, S., Jung, C. H., Hong, S. J., Kim, J., & Choi, S. H. (2018) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2018.7.2.77 · Cited by 3
Self-citationCoronary atherosclerotic plaque progression: contributing factors in statin-treated patients
Clark, D., Puri, R., & Nissen, S. E. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1833716 · Cited by 3
Carroll, C., Tappenden, P., Rafia, R., Hamilton, J., Chambers, D., Clowes, M., Durrington, P. N., Qureshi, N., & Wierzbicki, A. S. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0472-2 · Cited by 3
The Potential Role of Anti-PCSK9 Monoclonal Antibodies in the Management of Hypercholesterolemia
Lepor, N. E., Contreras, L., Desai, C., & Kereiakes, D. J. (2014) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0773 · Cited by 3
Einführung der PCSK9-Inhibitoren
Klose, G. (2016) · Herz · doi:10.1007/s00059-016-4428-2 · Cited by 3
Evolving Concepts in LDL-Lowering Strategies: Are We There?
Cimmino, G., Loffredo, F. S., Arena, G., & Golino, P. (2016) · Journal of Clinical & Experimental Cardiology · doi:10.4172/2155-9880.1000468 · Cited by 3
PCSK9 inhibition: A promise fulfilled?
Solaru, K. W., Mohan, C., & Rocco, M. B. (2016) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.83.s2.05 · Cited by 3
Inoue, I., Kubota, R., Yanagi, S., Akita, M., Nakano, T., Katayama, S., Shimada, A., & Noda, M. (2017) · Open Journal of Molecular and Integrative Physiology · doi:10.4236/ojmip.2017.71001 · Cited by 3
FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
Hassan, M. S. (2017) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2017.13 · Cited by 3
Malvandi, A. M., Canclini, L., Alliaj, A., Magni, P., Zambon, A., & Catapano, A. L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1801628 · Cited by 3
Kunimura, A., Miura, K., Segawa, H., Torii, S., Kondo, K., Hisamatsu, T., Kadota, A., Fujiyoshi, A., Yano, Y., Nakagawa, Y., et al. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63549 · Cited by 3
Evolocumab for the treatment of homozygous familial hypercholesterolaemia
Blom, D. J., & Marais, A. D. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1189323 · Cited by 3
Self-citationNEW POSSIBILITIES OF HYPOLIPIDEMIC THERAPY
Benimetskaya, K., Atyukov, P. A., Astrakov, S. V., & Ragino, Y. I. (2017) · Siberian medical review · doi:10.20333/2500136-2017-4-65-81 · Cited by 3
Murín, J. (2017) · Vnitřní lékařství · doi:10.36290/vnl.2017.085 · Cited by 3
Nonstatin Therapy for Dyslipidemia
Ahmed, H. M., & Nissen, S. E. (2018) · Circulation Research · doi:10.1161/circresaha.118.313829 · Cited by 3
The Many Lives of PCSK9: Therapeutic Implications
Pressly, J. D., & Fornoni, A. (2022) · Kidney360 · doi:10.34067/kid.0003272022 · Cited by 3
PCSK9 Inhibitor and Potential Decreased Risk of Neoplasms, Especially in Females: A Meta-Analysis
Wei, T., Li, Z., Lin, C., Yang, Y., Tie, C., Cai, X., Lv, F., Yang, W., & Ji, L. (2025) · Pharmaceuticals · doi:10.3390/ph18081095 · Cited by 2
Lipid-lowering effect of evolocumab in hypertriglyceridemia-induced acute pancreatitis
Chen, H., Li, X., Chen, J., Zhao, Y., Zhang, W., Li, H., & Qi, X. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178148 · Cited by 2
Deng, Z. C., Sun, H., Cheng, J. Q., Zhao, R., Xie, J., Song, Y., Zhao, Y., Lin, C., Hu, B., Gong, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202519698 · Cited by 2
Zayed, J. A., Al‐Awamleh, N. A., Hamad, M., Hdaib, M. I. M., & Ayesh, H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70944 · Cited by 2
Wang, H., Mao, Y.-C., Qi, S.-F., Xu, X., Zhang, Z., Geng, C., Song, K., & Tian, Q. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00651-7 · Cited by 2
Molecular Therapeutics in Development to Treat Hyperlipoproteinemia
Ahmad, M., & Hegele, R. A. (2025) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00768-0 · Cited by 3
Late-breaking Trials from the 2016 American Heart Association's Scientific Sessions
Buchanan, K. D., Alraies, M. C., Kajita, A. H., Rogers, T., Koifman, E., & Steinvil, A. (2016) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2016.12.002 · Cited by 2
Јаnkovic, S., Tešić, D., Anđelković, J., & Kostić, M. (2018) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2018.1501679 · Cited by 2
Liu, C., Ruan, Y., Huang, R., Fang, L., Wu, T., Lv, Y., Cui, L., Liao, Y., Wang, B., Chen, Z., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03747-w · Cited by 2
Emerging Implications of Elevated Lipoprotein(a) Levels in Coronary Artery Bypass Graft Surgery
Patel, S. K., Badross, M. S., Dhingra, N. K., Moroney, M., Casey, J. H., Hassan, S. M. A., Khan, T., Hess, D. A., Koschinsky, M. L., Teoh, H., et al. (2025) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2025.01.013 · Cited by 2
Novedades cardiovasculares 2013/2014
Cuende, J. I., Lahoz, C., Armario, P., García-Alegría, J., Ena, J., de Casasola, G. G., & Mostaza, J. M. (2014) · Revista Clínica Española · doi:10.1016/j.rce.2014.07.012 · Cited by 2
The year in cardiology 2014: coronary intervention
Iqbal, J., Serruys, P. W. J. C., Albuquerque, F. N., & Wijns, W. C. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu487 · Cited by 2
Interventions for Extracranial Carotid Artery Stenosis: An Update
Huang, J. F., & Meschia, J. F. (2016) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-016-0455-9 · Cited by 2
Gómez, J. R. M., Duque, L. N. H., & Palacio, J. J. C. (2015) · Revista Med · doi:10.18359/rmed.1744 · Cited by 2
PCSK9 Inhibitor Non-Response In A Patient With Preserved LDL Receptor Function: A Case Study*
Losh, C., & Underberg, J. A. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.03.097 · Cited by 2
PCSK9 as a Biomarker of Cardiovascular Disease
Ooi, T. C., & Abujrad, H. (2016) · Springer eBooks · doi:10.1007/978-94-007-7678-4_20 · Cited by 2
Identifying and Preventing Cardiac Risk Factors from Fetal Life
Mahan, V. L. (2018) · Journal of Pediatrics and Pediatric Medicine · doi:10.29245/2578-2940/2018/4.1131 · Cited by 3
Varghese, S., Ohlow, M., & Kumar, N. (2019) · Heart and Mind · doi:10.4103/hm.hm_17_19 · Cited by 2
Skutki hamowania funkcji PCSK9 w obrębie wybranych tkanek *
Maligłówka, M., Bułdak, Ł., Okopień, B., & Bołdys, A. (2021) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0014.9127 · Cited by 2
Update on PCSK9 therapies for the treatment of dyslipidemia
Singh, A., & Davidson, M. H. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1131120 · Cited by 2
Anti-inflammatory and Atheroprotective Properties of Omega-3 Polyunsaturated Fatty Acids
Sorokin, A. V., Yang, Z. H., & Remaley, A. T. (2016) · Journal of Clinical & Experimental Cardiology · doi:10.4172/2155-9880.1000478 · Cited by 2
2019 clinical trials in lipid lowering
Feldman, D. I., Pacor, J., Blumenthal, R. S., & Nasir, K. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000757 · Cited by 2
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_44 · Cited by 2
Cardiovascular Safety of Evolocumab: a Systematic Review and Meta-Analysis
Krittanawong, C., Kitai, T., Zhang, H., & Sun, T. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6703-0 · Cited by 2
Landmesser, U., & Makhmudova, U. (2023) · Circulation · doi:10.1161/circulationaha.123.065407 · Cited by 2
van Bruggen, F. H., Zuidema, S. U., & Luijendijk, H. J. (2024) · BMC Medical Research Methodology · doi:10.1186/s12874-024-02260-z · Cited by 2
Niu, Q., Wang, Q., Chen, F., & Li, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1626681 · Cited by 1
Hamzah, K. A., Kurmasha, Y. H., Abdrabo, M. F., Srour, M. F., Al‐Shammari, A. S., Badi, M., Shweliya, M. A., Jena, N. K., & Sattar, Y. (2026) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2026.200590 · Cited by 1
Erlich, M. N., Ghidanac, D., Mejía, S. B., Ayoub‐Charette, S., Combe, C. V., Khan, T. A., Ramdath, D. P., Crewson, H., Beck, A., Silva, C. J., et al. (2026) · Nutrients · doi:10.3390/nu18071026 · Cited by 1
Feng, B., Shi, Y., Xu, J., Hu, M., Liang, S., Li, Y., & Gan, W. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00029 · Cited by 1
In vivo epigenome editing reduces circulating lipids and attenuates atherosclerosis in mice
Wang, W., Zhang, Y. L., Chen, L., Lu, Y., He, Y., Cheng, H., Tang, T. S., Li, X., Zhang, J., Liu, Y., et al. (2026) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2026.04.004 · Cited by 1
Patient Preferences for Lipid-Lowering Agents in Hypercholesterolemia: A Discrete Choice Experiment
Yiu, H. H. E., Yan, V. K. C., Au, C. C. L., Deng, E. K., Wong, M. C. S., Yan, B. P., Wong, W. C. W., Liu, S. Y., Wong, C. K., Chan, E. W., et al. (2026) · Value in Health Regional Issues · doi:10.1016/j.vhri.2026.101662 · Cited by 1
The PCSK9 Inhibitors: A Lipid-lowering Therapy to Treat Atherosclerotic Cardiovascular Diseases
Priyanka, F., Durga, F., Affan, M., & Venjhraj, F. (2025) · Nature Cell and Science · doi:10.61474/ncs.2024.00056 · Cited by 1
Wang, B., Zeng, H., Yuan, Y., Yu, L., Zhang, Z., Ma, Y., & Wu, W. (2025) · Healthcare and Rehabilitation · doi:10.1016/j.hcr.2025.100053 · Cited by 1
Evolocumab-induced allergic reaction in a post-partial gastrectomy patient: A case report
Hong, X., Jiang, X., Xu, X., Xiong, F., & Huang, X. (2025) · Medicine · doi:10.1097/md.0000000000046793 · Cited by 1
Wu, T., Zhao, X., Xiao, M., Deng, J., Chen, Z., Cheng, D., Pan, S., Liu, X., Wu, Y., & Huang, K.-H. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.047411 · Cited by 1
Combination Therapy with Statins
Singh, A., & Davidson, M. H. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.005 · Cited by 1
Perspektiven zu cholesterinwirksamer Behandlung 2014
Klose, G., Schulz, R., & Köenig, W. (2014) · CardioVasc · doi:10.1007/s15027-014-0521-8 · Cited by 1
Metadata
- Authors
- Blom, D. J., Hala, T., Bolognese, M., Lillestol, M. J., Toth, P. D., Burgess, L., Ceska, R., Roth, E., Koren, M. J., Ballantyne, C. M., Monsalvo, M. L., Tsirtsonis, K., Kim, J. B., Scott, R., Wasserman, S. M., & Stein, E. A.
- Affiliations
- University of Cape Town (ZA)
- National Institutes of Health (US)
- Midwest Institute for Clinical Research (US)
- Stellenbosch University (ZA)
- Sterling Research Group (US)
- Jacksonville Center for Clinical Research (US)
- Houston Methodist (US)
- Amgen (United States) (US)
- Amgen (United Kingdom) (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-08
- Volume
- 370
- Issue
- 19
- Pages
- 1809-1819
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2155259933
- Semantic Scholar
- 8d480541d9ba40d0cf45fea465f3b42bfc2b2f19
- Cited by
- 720
- References
- 16
- Citations by year
- 2026: 25 · 2025: 35 · 2024: 44 · 2023: 44 · 2022: 26 · 2021: 33 · 2020: 46 · 2019: 49 · 2018: 62 · 2017: 92 · 2016: 110 · 2015: 103 · 2014: 48
- FWCI
- 116.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Open University of Cape Town (University of Cape Town) (submittedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- evolocumab, PCSK9 inhibition, hyperlipidemia, LDL cholesterol lowering, monoclonal antibodies, atorvastatin, ezetimibe, apolipoprotein B, lipoprotein(a), triglycerides, non-HDL cholesterol, treatment safety
- MeSH terms
- Atorvastatin, Ezetimibe, Proprotein Convertase 9, Adult, Aged, Antibodies, Monoclonal, Azetidines, Combined Modality Therapy, Double-Blind Method, Female, Heptanoic Acids, Humans, Hyperlipidemias, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Serine Endopeptidases, Least-Squares Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Proprotein Convertases, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
